<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="207">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05158452</url>
  </required_header>
  <id_info>
    <org_study_id>OSU-20380</org_study_id>
    <secondary_id>NCI-2021-01883</secondary_id>
    <secondary_id>R01CA248739</secondary_id>
    <nct_id>NCT05158452</nct_id>
  </id_info>
  <brief_title>Development of a Genetic Counseling Patient Preference Intervention for Women at Elevated Risk for Breast Cancer</brief_title>
  <official_title>Development of a Genetic Counseling Patient Preference Intervention for Women at Elevated Risk for Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ohio State University Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Ohio State University Comprehensive Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study develops a genetic counseling patient preference intervention for women at&#xD;
      elevated risk for breast cancer. This study aims to develop an intervention that may deliver&#xD;
      educational videos about breast cancer, heredity, multigene tests results and polygenic risk&#xD;
      score, provide multigene and polygenic test results, obtain information about patients'&#xD;
      questions/ concerns about test results to use in post-genetic test counseling, and determine&#xD;
      patient preference (e.g. telephone) for receipt of post-genetic test counseling.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVE:&#xD;
&#xD;
      I. Develop the Genetic Counseling Patient Preference (GCPP) intervention in collaboration&#xD;
      with community members.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
      Participants attend a focus group over 90-120 minutes providing feedback on GCPP&#xD;
      intervention.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 30, 2022</start_date>
  <completion_date type="Anticipated">December 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Development of Genetic Counseling Patient Preference (GCPP) intervention</measure>
    <time_frame>Up to 2 years</time_frame>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">16</enrollment>
  <condition>Breast Carcinoma</condition>
  <arm_group>
    <arm_group_label>Observational (focus group)</arm_group_label>
    <description>Participants attend a focus group over 90-120 minutes providing feedback on GCPP intervention.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Discussion</intervention_name>
    <description>Attend a focus group</description>
    <arm_group_label>Observational (focus group)</arm_group_label>
    <other_name>Discuss</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Women at elevated risk for breast cancer&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Female&#xD;
&#xD;
          -  Ages 35-64&#xD;
&#xD;
          -  Known elevated risk for breast cancer&#xD;
&#xD;
          -  The ability to speak and read English&#xD;
&#xD;
          -  Provide written consent&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kevin Sweet, MS, LGC</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ohio State University Comprehensive Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>The Ohio State University Comprehensive Cancer Center</last_name>
    <phone>800-293-5066</phone>
    <email>OSUCCCClinicaltrials@osumc.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ohio State University Comprehensive Cancer Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Kevin Sweet, MS, LGC</last_name>
      <phone>614-293-6694</phone>
      <email>kevin.sweet@osumc.edu</email>
    </contact>
    <investigator>
      <last_name>Kevin Sweet, MS, LGC</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://cancer.osu.edu</url>
    <description>The Jamesline</description>
  </link>
  <verification_date>December 2021</verification_date>
  <study_first_submitted>December 3, 2021</study_first_submitted>
  <study_first_submitted_qc>December 3, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 15, 2021</study_first_posted>
  <last_update_submitted>December 3, 2021</last_update_submitted>
  <last_update_submitted_qc>December 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ohio State University Comprehensive Cancer Center</investigator_affiliation>
    <investigator_full_name>Kevin Sweet</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

